“…However, in an analysis of the Society of Thoracic Surgeons national database by Arnaoutakis et al that was published a little more than a decade after the initial GUSTO trial, 51.7% of the patients were in cardiogenic shock at admission or prior to intervention, with a 30‐day mortality rate of 42.9% 6 . In recent studies with smaller sample sizes, however, perioperative mortality ranges from a minimum of 4.3% 13 to a maximum of 65.0%, 10 with the majority of studies ranging between 20% and 40% 7‐9,14,15 . In patients with pVSD, pre‐operative CS appears to be the most important variable among risk factors for in‐hospital mortality, and many authors have been able to substantiate this link over the years, whereby overall mortality usually increases with the increase in the number of patients in CS 4,6,9,10,16 .…”